Figure 3.

Untargeted diagnostic screening (UDS): (1) Overview of UDS prototole (2) serum extracts are analyzed by global LC-HRMS acquisition; (3) data treatment reveals and ranks, via (4) feature statistics, compounds of interest in a sick patient (test sample) in comparison to healthy population (control samples); features are (5) filtered and (6) identified for (7) biomedical interpretation and preliminary diagnosis prior confirmatory, targeted, and quantitative analyses. A feature is an ion-retention time entity that corresponds roughly to a compound.